a4548c

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under the

Securities Exchange Act of 1934

CommissionFile Number 001-14978

(Registrant’sname)

Building 5, Croxley Park, Hatters Lane

Watford, England, WD18 8YE

(Addressof principal executive office)

Indicateby check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F.

Form20-F ✔ Form 40-F__

Smith+Nephew Announces Capital Markets Days in London and NewYork

Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technologycompany, announces that it will host Capital Markets Days forinstitutional investors and financial analysts in London and NewYork on Monday 8 and Thursday 11 December 2025respectively.

The London event willintroduce Smith+Nephew's new strategy following the conclusion ofthe 12-Point Plan, including mid-term priorities and financialgoals. This will be held at The Royal College of Surgeons from 1pmto 5pm GMT / 8am to 12pm EST on 8 December.

The New York event willprovide greater detail on Smith+Nephew's innovative portfolio thatwill drive the next phase of growth, with insight from Smith+Nephewcustomers and Key Opinion Leaders. This event will be held at theNew York Stock Exchange from 2pm to 6pm GMT / 9am to 1pm EST on 11December.

Both events will be ledby Chief Executive Officer Deepak Nath, accompanied by ChiefFinancial Officer John Rogers and members of the ExecutiveCommittee. Further information will be provided in due course, andparticipants are encouraged to attend both events, either in personor virtually.

Inperson attendance at these events requires pre-registration.Investors and analysts should register via Smith+Nephew's websiteat https://www.smith-nephew.com/en/about-us/investors.

The sessions will alsobe webcast and the presentations made available via thewebsite.

Emily Heaven / Cora McCallum +44 (0) 1923 477433

Charles Reynolds +44 (0) 1923 477314

Smith+Nephew is a portfolio medical technology business focused onthe repair, regeneration and replacement of soft and hard tissue.We exist to restore people's bodies and their self-belief by usingtechnology to take the limits off living. We call this purpose'Life Unlimited'. Our 18,000 employees deliver this mission everyday, making a difference to patients' lives through the excellenceof our product portfolio, and the invention and application of newtechnologies across our three global business units ofOrthopaedics, Sports Medicine & ENT and Advanced WoundManagement.

Founded in Hull, UK, in1856, we now operate in more than 100 countries, and generatedannual sales of $5.8 billion in 2024. Smith+Nephew is a constituentof the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and'Smith+Nephew' are used to refer to Smith & Nephew plc and itsconsolidated subsidiaries, unless the context requiresotherwise.

Formore information about Smith+Nephew, please visit www.smith-nephew.com andfollow us on X, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may ormay not prove accurate. For example, statements regarding expectedrevenue growth and trading profit margins, market trends and ourproduct pipeline are forward-looking statements. Phrases such as"aim", "plan", "intend", "anticipate", "well-placed", "believe","estimate", "expect", "target", "consider" and similar expressionsare generally intended to identify forward-looking statements.Forward-looking statements involve known and unknown risks,uncertainties and other important factors that could cause actualresults to differ materially from what is expressed or implied bythe statements. For Smith+Nephew, these factors include: conflictsin Europe and the Middle East, economic and financial conditions inthe markets we serve, especially those affecting healthcareproviders, payers and customers; price levels for established andinnovative medical devices; developments in medical technology;regulatory approvals, reimbursement decisions or other governmentactions; product defects or recalls or other problems with qualitymanagement systems or failure to comply with related regulations;litigation relating to patent or other claims; legal and financialcompliance risks and related investigative, remedial or enforcementactions; disruption to our supply chain or operations or those ofour suppliers; competition for qualified personnel; strategicactions, including acquisitions and disposals, our success inperforming due diligence, valuing and integrating acquiredbusinesses; disruption that may result from transactions or otherchanges we make in our business plans or organisation to adapt tomarket developments; relationships with healthcare professionals;reliance on information technology and cybersecurity; disruptionsdue to natural disasters, weather and climate change relatedevents; changes in customer and other stakeholder sustainabilityexpectations; changes in taxation regulations; effects of foreignexchange volatility; and numerous other matters that affect us orour markets, including those of a political, economic, business,competitive or reputational nature. Please refer to the documentsthat Smith+Nephew has filed with the U.S. Securities and ExchangeCommission under the U.S. Securities Exchange Act of 1934, asamended, including Smith+Nephew's most recent annual report on Form20-F, which is available on the SEC's website at www. sec.gov, fora discussion of certain of these factors. Any forward-lookingstatement is based on information available to Smith+Nephew as ofthe date of the statement. All written or oral forward-lookingstatements attributable to Smith+Nephew are qualified by thiscaution. Smith+Nephew does not undertake any obligation to updateor revise any forward-looking statement to reflect any change incircumstances or in Smith+Nephew's expectations.

◊ Trademarkof Smith+Nephew. Certain marks registered in US Patent andTrademark Office.

Pursuantto the requirements of the Securities Exchange Act of 1934, theregistrant has duly caused this report to be signed on its behalfby the undersigned, thereunto duly authorized.


		Smith & Nephew plc
		(Registrant)


Date:October 08, 2025	By:	/s/Helen Barraclough
		HelenBarraclough
		CompanySecretary